Targeted conjugates containing modified siRNA

JP2023548295A5Inactive Publication Date: 2024-11-13ARBUTUS BIOPHARMA CORPORAT ION
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023525517
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-06
Filing Date
2021-11-05
Publication Date
2024-11-13
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Benefits of technology

【0005】 本発明の他の目的、特徴、及び利点は、以下の詳細な説明及び図面から当業者に明らかになる。

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The present invention provides a conjugate comprising a nucleic acid (e.g., a double-stranded siRNA molecule) and a targeting moiety, an siRNA, and an optional linking group. The conjugate is useful for targeting the siRNA.
Need to check novelty before this filing date? Find Prior Art

Claims

1. A compound of formula (I) or a salt thereof: R 1 -L-R 2 (I) [In the formula, R 1 is a targeting ligand comprising one or more saccharide groups; L is an optional linker; R 2 is the following formula: [Formula 1] wherein B is a nucleobase.

2. Compound of formula (II): [Case 2] [In the formula, R 1 is a targeting ligand comprising one or more saccharide groups; L 1 is absent or a linking group; L 2 is absent or a linking group; R 2 is the following formula: [C3] (B is a nucleobase); Ring A is absent, a 3- to 20-membered cycloalkyl, a 5- to 20-membered aryl, a 5- to 20-membered heteroaryl, or a 3- to 20-membered heterocycloalkyl; Each R A are independently hydrogen, hydroxy, CN, F, Cl, Br, I, -C 1-2 Alkyl-OR B , C 1-10 Alkyl C 2-10 Alkenyl, and C 2-10 alkynyl; 1-10 Alkyl C 2-10 Alkenyl, and C 2-10 Alkynyl includes halo, hydroxy, and C 1-3 optionally substituted with one or more groups independently selected from alkoxy; R B is hydrogen, a protecting group, a covalent bond to a solid support, or a bond to a linking group attached to a solid support; n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

2. The compound or salt of claim 1, which is:

3. Compound of formula (IIg): [C4] [In the formula, B is -N- or -CH-; L 2 is C optionally substituted with hydroxyl or halo 1-4 alkylene-O-; n is 0, 1, 2, 3, 4, 5, 6, or 7.

3. The compound or salt of claim 2, which is:

4.

5. [In the formula, Q is -L 1 -R 1 and R' is C 1-9 Alkyl, C 2-9 Alkenyl or C 2-9 alkynyl; 1-9 Alkyl, C 2-9 Alkenyl or C 2-9 The alkynyl is optionally substituted with halo or hydroxyl.

4. The compound or salt of claim 3, selected from the group consisting of:

5. R 1 is the following formula: [C6] [In the formula, B 1 is a trivalent group containing from about 1 to about 20 atoms; L 1 , T 1 , and T 2 is covalently bonded to B 2 is a trivalent group containing from about 1 to about 20 atoms, T 1 , T 3 , and T 4 is covalently attached to B 3 is a trivalent group containing from about 1 to about 20 atoms, T 2 , T 5 , and T 6 is covalently attached to T 1 is absent or a linking group; T 2 is absent or a linking group; T 3 is absent or a linking group; T 4 is absent or a linking group; T 5 is absent or a linking group; T 6 is absent or a linking group. The compound or salt according to any one of claims 1 to 4, having the formula:

6. B 2 and B 3 are each independently [C7] 6. The compound or salt of claim 5, selected from the group consisting of:

7.

8. 2. The compound or salt of claim 1, which is:

8.

9. 2. The compound or salt of claim 1, which is:

9. R 2 The compound or salt according to any one of claims 1 to 8, which is an siRNA comprising SEQ ID NO: 2, 3, 4, 5, 6, 7, 8, 10, or 11 as the antisense strand.

10. R 2 The compound or salt according to any one of claims 1 to 8, which is an siRNA comprising SEQ ID NO: 6 or 7 as an antisense strand.

11. R 2 The compound or salt according to any one of claims 1 to 8, wherein the siRNA is selected from any one of siRNAs 2 to 9.

12.

10. [In the formula, R 2 ' is an siRNA comprising SEQ ID NO: 2, 3, 4, 5, 6, 7, 8, 10, or 11 as the antisense strand. or a salt thereof.

13.

11. or a salt thereof.

14.

12. or a salt thereof.

15. A pharmaceutical composition comprising a compound according to any one of claims 1 to 14, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable carrier.

16. 115. A composition for treating Hepatitis B virus infection in a human, comprising a compound according to any one of claims 9 to 114, or a pharma- ceutically acceptable salt thereof.

17. The composition of claim 16 , wherein the compound or salt thereof is administered in combination with another therapeutic agent.

18. An siRNA molecule selected from any one of siRNAs 2 to 9.